{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Received any Treatment for Ocular Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Encouraged Adherence to Eye Drop Regimen"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Increased Eye Drops"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Received a new prescription - Eye drops/ointment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Number of participants receiving treatment for ocular toxicity during BLENREP therapy, as categorized by type of treatment.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Ophthalmology: Treatments for Ocular Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}